Recent advances in deciphering oligodendrocyte heterogeneity with single-cell transcriptomics

Lukas Valihrach1,2*, Zuzana Matusova1,3, Daniel Zucha1,4, Ruslan Klasse1,5, Sarka Benesova1,4, Pavel Abaffy1, Mikael Kubista1,6 and Miroslava Anderova2*

1Laboratory of Gene Expression, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czechia, 2Department of Cellular Neurophysiology, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czechia, 3Faculty of Science, Charles University, Prague, Czechia, 4Department of Informatics and Chemistry, Faculty of Chemical Technology, University of Chemistry and Technology, Prague, Czechia, 5Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Czechia, 6TATAA Biocenter AB, Gothenburg, Sweden

Oligodendrocytes (OL) have been for decades considered a passive, homogenous population of cells that provide support to neurons, and show a limited response to pathological stimuli. This view has been dramatically changed by the introduction of powerful transcriptomic methods that have uncovered a broad spectrum of OL populations that co-exist within the healthy central nervous system (CNS) and also across a variety of diseases. Specifically, single-cell and single-nucleus RNA-sequencing (scRNA-seq, snRNA-seq) have been used to reveal OL variations in maturation, myelination and immune status. The newly discovered immunomodulatory role suggests that OL may serve as targets for future therapies. In this review, we summarize the current understanding of OL heterogeneity in mammalian CNS as revealed by scRNA-seq and snRNA-seq. We provide a list of key studies that identify consensus marker genes defining the currently known OL populations. This resource can be used to standardize analysis of OL related datasets and improve their interpretation, ultimately leading to a better understanding of OL functions in health and disease.

KEYWORDS
oligodendrocyte, heterogeneity, scRNA-seq, snRNA-seq, populations, marker genes

Introduction

OLs represent a type of glial cells found in the CNS of invertebrates and vertebrates. Their primary role is to envelop the axons of the neurons in myelin, which provides insulation and maintains the electrical impulse conduction. Since their first description in 1921, they have been considered a heterogeneous population, displaying variable

Frontiers in Cellular Neuroscience 01 frontiersin.org
Our motivation is to provide the community a unified overview on single-cell and single-nucleus transcriptomic technologies. Understanding of OL heterogeneity in health and disease based on their variations related to differentiation state, developmental origin, anatomical site, age and sex (for an extensive review, see Seeker and Williams, 2022).

A completely new area of OL characterization started with the advent of single-cell transcriptomic techniques allowing analysis of thousands of cells, each characterized by the activity of thousands of genes. The first landmark studies characterizing OL transcriptional heterogeneity were performed on single cells in healthy animals (Zeisel et al., 2015, 2018; Marques et al., 2016). The introduction of protocols for the analysis of single nuclei isolated from archived samples facilitated the expansion and application of the technique to investigations from human tissues. Currently, we are experiencing a boom in transcriptional studies characterizing OLs in a variety of pathological conditions and disease states, rapidly extending our understanding of OL heterogeneity. However, with the increasing number of scRNA-seq and snRNA-seq studies, and the enormous complexity of the information embedded within each dataset, there is a new challenge for OL researchers that is the comparison and the interpretation of newly acquired data with existing studies. Although this step is not mandatory and often missed in reports, it provides an important insight into the general function of OLs, potentially transferring knowledge derived from one particular model to a broader spectrum of pathological states.

The process of data interpretation using other studies as reference is typically done by comparing selected marker genes to a defined OL population or by integrative analysis. The relation of OL populations is then assessed by the overlap of these marker genes or by enrichment type of analysis. The downside is that the calculation of marker genes is heavily influenced by the data processing and the particular downstream analysis, which biases the comparison of populations. Integrative analysis is therefore a more robust way to interpret new data (Stuart and Satija, 2019). Integration allows merging of data for the unified processing of multiple datasets, even if they are derived using different protocols or experimental models. Although more robust, this method is biased by the choice and settings of the integration tool. Finally, the choice of reference studies is of utmost importance. This is far from trivial as features of OL heterogeneity of interest may be hidden in studies characterizing completely unrelated biological questions.

To guide OL researchers in the wealth of current knowledge, we prepared a compact review summarizing the current understanding of OL heterogeneity in health and disease based on single-cell and single-nucleus transcriptomic technologies. Our motivation is to provide the community a unified overview of key transcriptomic studies dealing with OL heterogeneity in the mammalian CNS (Table 1) and consensus marker genes of selected OL populations (Table 2). We hope that the interpretation of new datasets with respect to those already available will lead to a standardization of OL nomenclature and our better understanding of their transcriptional heterogeneity.

### Oligodendrocyte heterogeneity in health

Since the advent of scRNA-seq analysis, there have been efforts to classify the CNS cell types. Early datasets comprised only of tens of cell types represented by hundreds to thousands of cells. The low proportion of OLs did not allow for their in-depth characterization or the OLs were not the primary focus of the studies. The first milestone deciphering OL heterogeneity was made in murine CNS, in studies published by researchers from the Division of Molecular Neurobiology at Karolinska Institute (Zeisel et al., 2015, 2018; Marques et al., 2016).

The study of Zeisel et al. (2015) focused on somatosensory cortex and hippocampal CA1 region of juvenile mice, and analyzed over 3,000 cells, including more than 800 OLs. Clustering revealed six OL populations representing various stages of maturation: post-mitotic, immature, pre-myelinating, myelinating, intermediate, and terminally differentiated post-myelination OLs. Marques et al. (2016) provided further details by analyzing over 5,000 cells of OL lineage in 10 regions of murine juvenile and adult CNS. In total, they observed 12 clusters of OL lineage, representing a continuum from oligodendrocyte precursor cells (OPC) to mature OLs (OPC, COP, NFOL1-2, MFOL1-2, and MOL1-6; Table 2). Whereas the initial stages of OL maturation (to MFOL1-2) were found sequential and uniform across CNS regions, mature OLs showed regional specificity, being present in unique proportions in each brain region. Moreover, cells sampled from adult mice comprised mostly of OPCs and two populations of mature OLs (MOL5-6), while juvenile cells were represented by the full spectrum of the OL populations. Lastly, the study of Zeisel et al. (2018) expanded the scope of the previous datasets by analyzing 19 CNS regions, counting over half a million of cells, with a large fraction comprising of OLs. Their analysis identified 10 clusters of OL lineage (OPC, COPI-2, NFOL1-2, MFOL1-2, MOL1-3; Table 2), but even with the increased sample size, it did not reveal any additional OL subtypes beyond those already described by Marques et al. (2016). Notably, despite the large similarity of the two datasets, there was not a perfect cluster match, probably due to different scRNA-seq technology and data processing protocols used. These differences might be possible to remove with integrative analysis, standardizing the nomenclature, and defining a set of consensus marker genes for future studies. For now, the marker genes and the reference for interpretation of new datasets might be selected based on

### Table 1: Key transcriptomic studies dealing with OL heterogeneity

| Study                        | Regions/CNS Areas                          | Sample Size | OL Proportion |
|------------------------------|--------------------------------------------|-------------|---------------|
| Zeisel et al. (2015)         | Somatosensory cortex, hippocampal CA1       | 3,000       | N/A           |
| Marques et al. (2016)        | Multiple CNS regions                       | 5,000       | N/A           |

### Table 2: OL populations identified

| Population   | Description       | Regions | Sample Size |
|--------------|-------------------|---------|-------------|
| OPC, COP, NFOL1-2, MFOL1-2, MOL1-6 | Multistage OL maturation | 10 | 5,000 |
| COPI-2, NFOL1-2, MFOL1-2, MOL1-3 | Terminal OL differentiation | 19 | N/A |

Del Rio-Hortega, 1921. However, decades of subsequent research have led to the general understanding that OLs are instead a homogenous population of cells, without any major functional heterogeneity. It was not until recently that advances in single-cell analysis revealed a new spectrum and sources of OL heterogeneity, including their variations related to differentiation state, developmental origin, anatomical site, age and sex (for an extensive review, see Seeker and Williams, 2022).
| Study                          | Species (mouse/human) | Condition | Methods                  | # of OL cluster (incl. OPCs) | Significance                                                                 | Accession number (custom database if available) |
|-------------------------------|-----------------------|-----------|--------------------------|----------------------------|------------------------------------------------------------------------------|-----------------------------------------------|
| Zeisel et al. (2015)          | Mouse                 | Ctrl      | scRNA-seq                | 6                          | First large-scale scRNA-seq study of all cell types in mouse CTX and HC       | GSE60361 (link)                              |
| Marques et al. (2016)         | Mouse                 | Ctrl      | scRNA-seq                | 12                         | First large-scale OL focused scRNA-seq study in mouse CNS                     | GSE75330 (link)                              |
| Zeisel et al. (2018)          | Mouse                 | Ctrl      | scRNA-seq                | 10                         | First large-scale scRNA-seq of all cell types in mouse CNS                    | SRP135960 (link)                             |
| Falcao et al. (2018)          | Mouse                 | Ctrl, EAE | scRNA-seq                | 14                         | First scRNA-seq defining disease related OL clusters                          | GSE113973 (link)                             |
| Jakel et al. (2019)           | Human                 | Ctrl, MS  | snRNA-seq                | 9                          | First OL focused snRNA-seq of MS patients and healthy controls                | GSE118257 (link)                             |
| Mathys et al. (2019)          | Human                 | Ctrl, AD  | snRNA-seq                | 5                          | First large-scale snRNA-seq of AD patients and healthy controls               | syn18485175 (link)                           |
| Floriddia et al. (2020)       | Mouse                 | Ctrl, SCI | ISH/ISS, scRNA-seq       | 11                         | Spatial distribution of mature OLs in WM and GM of murine brain and SC        | GSE128525 (link)                             |
| Zhou et al. (2020)            | Both                  | Ctrl, AD  | snRNA-seq                | 2–5                        | Description of SerpinA3 + C4b reactive OLs in AD mice                          | GSE140511, syn21125841                      |
| Chen et al. (2020)            | Both                  | Ctrl, AD  | ISS, ST                  | –                          | Spatial characterization of plaque-induced transcriptomic response in AD      | GSE152586, syn22153884                      |
| Lee et al. (2021)             | Mouse                 | Ctrl, AD  | scRNA-seq                | 7–8                        | Description of two disease-associated OL clusters across three AD models       | GSE160512, GSE181786, GSE153895              |
| Yao et al. (2021)             | Mouse                 | Ctrl      | sc + snATAC-seq, snmC-seq2 | 9                          | BCCN—transcriptomic and epigenomic cell atlas of mouse CTX                   | nemo:dat-ch1ngb7 (link)                      |
| Bakken et al. (2021)          | Both                  | Ctrl      | snRNA-seq, snmC-seq2, SNARE-seq2 | 4–9                      | BICCN—comparison of motor CTX in human, marmoset and mouse                   | nemo:dat-ek5dbmu (link)                      |
| Russ et al. (2021)            | Mouse                 | Ctrl      | sc + snRNA-seq           | 5                          | Harmonized atlas of mouse SC cell types (six integrated datasets)            | GSE158380 (link)                             |
| Morabito et al. (2021)        | Human                 | Ctrl, AD  | snRNA-seq, snATAC-seq    | 14–15                      | Chromatin accessibility and transcriptomic characterization of AD              | syn22079621 (link)                           |
| Bartosovic et al. (2021)      | Mouse                 | Ctrl      | scCUT&Tag                | 5                          | scCUT&Tag profiling of histone modification and TFs in murine OLs             | GSE163352 (link)                             |
| Hilscher et al. (2022)        | Mouse                 | Ctrl      | ISS                      | 12                         | Spatial distribution of OL populations from Marques et al. (2016)             | Data not available                           |
| Sadick et al. (2022)          | Human                 | Ctrl, AD  | snRNA-seq                | 7                          | OL integration in multiple human AD datasets                                  | GSE167494 (link)                             |
| Kengsboch et al. (2022)       | Mouse                 | Ctrl, EAE, aging | scRNA-seq            | 14                         | Definition of DOLs in murine models of AD, MS and aging                       | GSE202297                                   |
| Kaya et al. (2022)            | Mouse                 | Aging     | scRNA-seq                | 4–7                        | Identification of interferon-responsive OLs during WM aging                   | Data not yet released                        |
| Yadav et al. (2022)           | Human                 | Ctrl      | snRNA-seq, ST            | 8                          | Cellular taxonomy of adult human SC                                           | GSE190442 (link)                             |
| Meijer et al. (2022)          | Both                  | Ctrl, EAE | snATAC-seq, multimune    | 12                         | In-depth epigenomic analysis of immune genes in OLs                          | GSE166179 (link)                             |
| Pandey et al. (2022)          | Both                  | AD, MS    | sc + snRNA-seq, smFISH   | 4–17                       | Characterization of three OL activation states across disease models          | GSE180041, GSE182846 (link)                  |

*For a curated database of all available single-cell transcriptomics studies with key experimental information (see Svensson et al., 2020). Ctrl, healthy conditions; EAE, experimental autoimmune encephalomyelitis; MS, multiple sclerosis; AD, Alzheimer’s disease; SCI, spinal cord injury; ISH, in situ hybridization; ISS, in situ sequencing; snATAC-seq, single-nucleus assay for transposase-accessible chromatin using sequencing; snmC-seq2, single nucleus methylcytosine sequencing; SNARE-seq2, single-nucleus chromatin accessibility and messenger RNA expression sequencing; snRNA/ATAC multimune, Chromium Single Cell Multimune ATAC + Gene Expression; ST, Spatial transcriptomics (Visium, 10x Genomics); smFISH, multiplexed single-molecule fluorescence in situ hybridization; CTX, cortex; HC, hippocampus; WM/GM, white/gray matter; SC, spinal cord; TFs, transcription factors; DOLs, disease-associated oligodendrocytes.
TABLE 2 Marker genes of selected OL populations as reported by authors.

| Study            | OL clusters | Gene signature                  | Source                                      |
|------------------|-------------|---------------------------------|---------------------------------------------|
| Marques et al. (2016) | OPC         | Pprr1, Mpgfr2, Serpin2c2, Cagp5, Vcan, Cagp4 | Supplementary Table 1—Top 6 marker genes of each branch of the dendrogram in Figure 1C (out of 50). For subclusters of the same differentiation stage, top 3 genes defining the stage and top2 genes defining the subcluster were selected. Of note, the list of genes is strictly identified according to “trinarization” scoring procedure developed by authors. |
|                  | COP         | C6h4, Neu, 43110035149Rk, Bmp4, Gpr17, Vcan |                                            |
|                  | NFOl1       | 9630013A20Rk, Arpc1b, Tmem2, Chn2, Mpeg2, Fcmd4a |                                            |
|                  | NFOl2       | 9630013A20Rk, Arpc1b, Tmem2, Mgp2, Draf1, Tigan2 |                                            |
|                  | MFol1       | Ctps, Tmem141, Opalin, 9630013A20Rk |                                            |
|                  | MFol2       | Ctps, Tmem141, Opalin, Mal, Ptgds, Evs2a-evs2b |                                            |
|                  | MOL1        | Apod, S wealthy, Fos, Fas, Dnaq1b1 |                                            |
|                  | MOL2        | Apod, S wealthy, Anxa5, Kib6, Mgp73 |                                            |
|                  | MOL3        | Apod, S wealthy, Car2, Cn52, Gad2 |                                            |
|                  | MOL4        | Apod, S wealthy, Serpinb1a, Neat1, Sep3 |                                            |
|                  | MOL5        | Apod, S wealthy, Cyp51, Dhr24, Pfdlm2 |                                            |
|                  | MOL6        | Apod, S wealthy, I33, Apoc, Pgd5 |                                            |
| Zeisel et al. (2018) | OPC         | Pdgfrα, Clq1f, Sapd2z, Emd1, Lhpf6 | Supplementary Table 4—Combination of markers genes uniquely identifying populations based on “trinarization” scoring procedure developed by authors. |
|                  | COP1        | Nerv4, Bcral, Bmp4, Pdk4, Lims2 |                                            |
|                  | COP2        | Tnr, Rid, Gpr17, Epp6, Pkci4 |                                            |
|                  | NFOl1       | Ccokor3, H2-Ab1, Ras2a, H2Sa, Tmem163 |                                            |
|                  | NFOl2       | Tmem2, Gm26834, Ras2a, Bpr2, Sema4d |                                            |
|                  | MFOL1       | Cip110, Snx33, Hhip, Tmem88b, Arpc2 |                                            |
|                  | MFOL2       | 2210011C24Rk, Wfj1k18, Tmem141, Birc2, Fam214a |                                            |
|                  | MOL1        | Opalin, Sni2, Efil1, Mal, Fppr144a |                                            |
|                  | MOL2        | Hapnp2, Dock5, Anil, Ugt8a, Gphi |                                            |
|                  | MOL3        | Kib6, Nbcz9, Calk1nc1, Rab57, 2700046467Rk |                                            |
| Falcao et al. (2018) | EAE_m1      | Serpina3m, Kib6, Serpin2c2, Serping1, Ifi27, C47, Iffh1 | Supplementary Figure 4B—Representatives for EAE-associated modules (sortable list in Supplementary Table 1) |
|                  | EAE_m2      | Ily2, C47, Serpin2a6, Kib6, Igrp, Igrp2, Calk13 | Supplementary Figure 8C—Selection of key markers (sortable list in Supplementary Table 4) |
|                  | EAE_m3      | Ptln1, Hifα6, Fatm107a, Pholy1, Calk41a, Saltai1 | Figure 2A—Three highlighted marker genes (sortable list in Supplementary Table 1) |
|                  | EAE_m4      | Aghga2p4, Mef2c, Chvero1, APOE, CD74, DOCK8, Plxdc2, Ell2, APBB1D, Hla.Dra, C3, Ftprrc | Figure 2D—Selected marker genes (full list in Supplementary Table 8) |
| Jakel et al. (2019) | ImOls      | ARHGA2P4, MEF2C, C10orf11, APOE, CD74, DOCK8, Plxdc2, ELL2, APBB1D, HLA.DRA, C3, FTPPRC | Supplementary Table 6—Top 6 marker genes for each consensus OL population (full list available) |
| Zhou et al. (2020) | Reactive Ols | C4b, Serpin3n, H2-41 | Supplementary Table 5—Sortable list of top 6 marker genes for each integrated OL dataset (see Supplementary Table 5) |
| Lee et al. (2021)  | MOL-DA1     | C4b, Serpin3n | Figure 3E—Selection of top markers of four integrated OL datasets (sortable list in Supplementary Table 5) |
|                  | MOL-DA2     | C4b, Serpin3n, Cdkn1a, Ddit3, Gad445a |                                          |
| Yao et al. (2021)  | OPC         | Pdgfrα | Supplementary Table 6—Top 6 marker genes for each consensus OL population (full list available) |
|                  | Oligo Cdnf1 | Col14a1, Cir, Gad2, Speck3, Sema4d, Gzp385b |                                          |
|                  | Oligo Enppt1 | Col14a1, Kcnip1, Cxcl14, Speck3, Sema4d, Chmna7 |                                          |
|                  | Oligo Enppt2 | Col14a1, Gad2, Cxcl14, Cir1, Rab3c, A380018L16Rk |                                          |
|                  | Oligo Enppt3 | Col14a1, Grik1, Cxcl14, Speck3, Sema4d, Necab1 |                                          |
|                  | Oligo Enppt4 | Kcnip1, Gad1, Cir4a1, Gad2, Grik1, Pax6 |                                          |
|                  | Oligo Opalin1 | Adar2b, Gpr14, Col14a1, Kcnip1, Gad1, Dab1 |                                          |
|                  | Oligo Opalin2 | A380018L16Rk, Kcnip1, Col14a1, Grik1, Sl2a13, Gad1 |                                          |
|                  | Oligo Opalin3 | Gpr1, Col14a1, Kcnip1, A380018L16Rk, Grik1, Gad1 |                                          |
|                  | Oligo Opalin4 | Gpr1, Kcnip1, Gad1, Mof, Shox2a, Neto1 |                                          |
| Sadick et al. (2022) | Int0       | Svep1, Linc01668, Plxdc2, Dystf |                                          |
|                  | Int1        | Ctnna2, Cnnp1, Stigal1a, Qdpr, Cynab |                                          |
|                  | Int2        | Fp23683.3, Mtna4, Mt-nna4, Mt-c02, Mt-Atp9 |                                          |
|                  | Int3        | Acnt2, Slc5a11, Rasgrf1, Linc00609, Ankrd19a |                                          |
|                  | Int4        | Scgcz, Mgda2, Cnnt1, Kcnp4, Fry |                                          |
|                  | Int5        | Rbfox1, Afta, Acsbg1, Col18a1 |                                          |
|                  | Int6        | Rfp2, Lucat1, Nav2, Camk2d, Neat1 |                                          |
| Kenigsbuch et al. (2022) | Dol1 | Serpin3n, C4b, H2-41, H2-42, B2m, E33, Kib6, Cdn9, Cd63 | Figure 2F—Highlighted marker genes |
| Pandey et al. (2022) | Dol1       | Serpin3n, C4b, Anxa2, Pphb, Thb3x, Staap3, Emp3, Pmr8b, S100a10, Tnfrsf1a, Coln1a1, Sema4f | Figure 2B—Selected marker genes (sortable list in Supplementary Table 2) |
|                  | MOL-DA1     | Serpin3n, C4b, Anxa2, Pphb, Thb3x, Staap3, Emp3, Pmr8b, S100a10, Tnfrsf1a, Coln1a1, Sema4f | Figure 2B—Selected marker genes (sortable list in Supplementary Table 2) |
|                  | MOL-DA2     | Cdkn1a1, Bax, Ddit3, Fos, Atf4, Egr1, Ccn1d1, Tnfrsf1a, Btg1, Egr2, Klf4, Fgfl7, Rard, Gdf15 | Figure 2F—Highlighted marker genes |
|                  | MOL-INF     | H2-41, Stat1, B2m, Igrp, Pbbmb, Igsml1, Iffh1, Iff7, Psmc1, Oaz1l2, H2-44, Tap1, Ebl2 | Figure 1G—Highlighted marker genes |
| Kaya et al. (2022)  | AROs        | C4b, Serpin3n, Socr, Vim, Gad445a, Bbc3 |                                          |
|                  | IROs        | Cyl227a, H2-2, Usp18, B2m, Stat1 |                                          |

OPC, oligodendrocyte precursor cells; COP, committed OL; NFOL, newly formed OL; MFOIL, myelin forming OL; MOL, mature OL; EAR, external anterior unencapsulated myelitis; ImOLs, immune OLs; MOL-DA, mature OL disease-associated; Int, integrated cluster of OLs; DolOs, disease-associated OLs; MOL-INF, mature OL interferon-associated; AROs, aging-related OLs; IROs, interferon-responsive OLs.
specific preferences. While the annotation used by Marques et al. (2016) has been applied in several subsequent studies (Falcao et al., 2018; Jakel et al., 2019; Floriddia et al., 2020; Bartosovic et al., 2021; Hilscher et al., 2022; Meijer et al., 2022; Pandey et al., 2022) and has become a standard in the field, an advantage of the Zeisel et al. (2018) annotation are the region-specific references rich in OLs, whose transcriptome was measured with the widely used 10x Genomics technology.

The classification of OLs in human CNS lagged behind the progress in mouse because of practical constrains in obtaining fresh samples for isolation of single cells. This has since changed with the introduction of protocols for the analysis of single nuclei, making it possible to process archived samples from the human brain biobanks. Using snRNA-seq, the first studies comprised of only a small number of OLs, limiting the annotation to a few clusters vaguely reflecting OL maturation (Habib et al., 2017; Lake et al., 2018). The first comprehensive characterization was a study describing altered OL heterogeneity in the white matter (WM) of five healthy donors and four individuals with progressive multiple sclerosis (MS) (Jakel et al., 2019). The authors identified seven clusters of mature OLs (Oligo1-6 and ImOLs), and clusters of OPC and committed oligodendrocyte precursors (COP). Integrative analysis with two previous datasets (Habib et al., 2017; Lake et al., 2018), re-annotated the Oligo6 cluster to an intermediate state, connecting the OPC and COP clusters with the mature OLs. Immune OLs (ImOLs) resembled the OPC and COP, but also expressed immune response related genes (Table 2).

Comparison of the human clusters with those previously obtained for the mouse OLs by Falcao et al. (2018), revealed similarities between the two species. In short, several other publications characterizing OL heterogeneity in CNS diseases have appeared (see next chapter). These reported varying numbers of clusters, most likely affected by the particular experimental design and data-processing pipeline used. It is likely that the complexity of human CNS will require dedicated efforts to determine and annotate the full spectrum of human OL heterogeneity. The first step in this direction was recently taken by Sadick et al. (2022), who integrated their data with three other studies (Grubman et al., 2019; Mathys et al., 2019; Zhou et al., 2020) identifying seven OL populations (Table 2), that appeared consistently across the datasets. However, an in-depth functional characterization was not performed. Of note, a similar integrative approach was used to create a harmonized atlas of mouse spinal cord cell types, but with limited details of OLs (Russ et al., 2021). Lastly, a comprehensive cellular taxonomy of the adult human spinal cord was recently released by Yadav et al. (2022), including an integrative analysis of mouse and human data.

Leaving the strictly OL-oriented research, the BRAIN Initiative Cell Census Consortium (BICCC) provides a great source of information that reveals additional layers of OL heterogeneity. Recently, BICCN released results of its first implementation phase presenting a multimodal cell census and an atlas of the mammalian primary motor cortex (BICCN, 2021). This massive resource provides a detailed transcriptomic and epigenomic cell atlas of the mouse primary motor cortex (Yao et al., 2021), including its spatial organization (Zhang et al., 2021) and comparison across human, marmoset (a new world monkey) and mouse (Bakken et al., 2021). The integrative analysis of seven scRNA-seq and snRNA-seq datasets led to the identification of 116 cell types, counting 59 classes of inhibitory and 31 classes of excitatory neurons, highlighting their large transcriptional diversity. Non-neuronal cells were categorized into 26 clusters, of which eight classes defined the populations of OLs (Table 2). As the BICCN is mostly a neuron-oriented effort, OL heterogeneity receives less attention and many of the interesting findings are waiting to be revealed by the community. The ultimate goal of BICCN is to perform the complete characterization of mouse and human CNS, and therefore another wealth of knowledge is expected in the upcoming years.

The recent developments in spatial transcriptomic technologies have made it possible to correlate OL transcriptional variation to their anatomical location. Floriddia et al. (2020) inspected spatial distribution of three populations of mature OLs in white and gray matter (GM) of murine brain and spinal cord. Specifically, they focused on populations of MOL1, MOL2, and MOL5/6 as defined by Marques et al. (2016), which showed the most distinctive expression profiles. Using a limited number of marker genes, the authors demonstrated different spatial preference and response to spinal cord injury. Further details were provided by Hilscher et al. (2022), who utilized probabilistic cell typing by in situ sequencing (pciSeq; Qian et al., 2020), and measured the expression of 124 marker genes of all 12 OL populations as described by Marques et al. (2016). The study focused on murine GM and WM in brain and spinal cord at postnatal, juvenile and young adult age, and revealed age and region related alterations in the composition of OL populations. Together, these two pioneering efforts provided the first hints for the understanding of the functional roles of the OL populations with respect to their anatomical locations.

**Oligodendrocyte heterogeneity in disease**

Falcao et al. (2018) represents a landmark study in understanding OL heterogeneity in disease, describing several disease specific OL populations in the spinal cord of mice induced by experimental autoimmune encephalomyelitis (EAE), which is an experimental model of multiple sclerosis (MS). In total, the authors identified 14 clusters, including three populations specific for the controls and five specific for EAE. Notably, even when separated into controls and EAE clusters, all the OLs resembled the clusters from Marques et al. (2016).
The analysis of major data trends revealed modules associated with EAE (Table 2), composed of genes related to interferon response, antigen processing and presentation via the major histocompatibility complex class I and II (MHC-I and -II) and immune protection, represented by the *Serpina3* gene family. Altogether, the data showed active immunomodulatory function of OLs in EAE, contesting the long-term dogma of their passive role with limited responsiveness to pathogenic stimuli. Extending the study, Jakel et al. (2019) performed an analysis of OLs in human samples with various levels of MS pathology. They identified a cluster of immune *CD74*+ OLs (ImOLs), resembling the data from the mouse EAE model. Notably, the recent study by Meijer et al. (2022) showed epigenomic priming of immune genes, further confirming OL immunomodulatory role. Moreover, the positioning of MS susceptibility single-nucleotide polymorphisms (SNPs) within the accessible regulatory regions of genes involved in immune regulation, suggested an altered function of OLs in disease progression.

The initial findings on OL heterogeneity in EAE/MS were soon accompanied by reports from intensive Alzheimer's disease (AD) research. Focusing on the murine AD model, Zhou et al. (2020) reported *Serpin3n*+ *C4b*+ reactive OL population (Table 2), specifically enriched in plaque-bearing regions. The gene signature markedly overlapped with EAE-enriched populations of OLs identified earlier by Falcao et al. (2018), suggesting a shared response of OLs in two distinct neurodegenerative models. The identical population of reactive OLs (annotated MOL-DA1) was subsequently confirmed by Lee et al. (2021), who assayed OL heterogeneity in AD models of amyloidosis and tauopathy (Table 2). Moreover, combined tau-amyloid pathology showed more extensive OL response, giving rise to population of OLs with strong Tp53 signaling (MOL-DA2), potentially leading to cell-cycle arrest and apoptosis, however, without any prominent loss of OLs. *In situ* hybridization (ISH) across brain regions confirmed the existence of cell clusters in affected areas and absence in control old animals except aged WM, suggesting age related neurodegenerative changes in this compartment. Notably, both astrocytes and OLs contributed substantially to the overall *C4b* and *Serpin3n* signal. Finally, a recent study of Kenigsbuch et al. (2022) largely confirmed the findings of the aforementioned reports by defining a population of disease-associated oligodendrocytes (DOLs, Table 2), whose gene signature was found in multiple CNS pathologies, including models of MS, AD and aging. Majorities of the 26 markers defining DOLs were related to immune response, and regulated by the transcription factor families Stat1/Irf, YY1/NF-xB and Sox9, in accordance with the findings of Meijer et al. (2022), who demonstrated a role of Stat1 in the immune OL population. Using human protein homologs of mouse Serpina3 as a key DOLs marker, authors detected *Serpina3* in human AD samples, demonstrating the relevance of the mouse data for human pathology. This, however, contrasts the report of Zhou et al. (2020), who did not detect reactive OLs in human AD samples using snRNA-seq, or Chen et al. (2020), who screened plaque regions for *C4a/C4b* and *Serpina3* transcripts by *in situ* sequencing (ISS).

Turning attention to human AD samples, OL heterogeneity has been interrogated in several studies investigating multiple brain regions (Del-Aguila et al., 2019; Grubman et al., 2019; Mathys et al., 2019; Lau et al., 2020; Zhou et al., 2020; Gerrits et al., 2021; Leng et al., 2021; Morabito et al., 2021; Sadick et al., 2022). Majority of studies concluded dysregulated OL functions in AD, including changes in differentiation, myelination and metabolic adaptation to neuronal degeneration. OLs have been accentuated as important players in disease progression, showing sexual dimorphism (Mathys et al., 2019), dysregulation of AD susceptible genes (Grubman et al., 2019), and expression of potential targets for novel AD therapeutics (Morabito et al., 2021). Interestingly, distinctive immune related response observed in murine models of MS and AD were not captured in any of the human studies, except for the very rare *CD74*+ OLs (counting for 0.001% of all OLs) identified by Morabito et al. (2021) and a minor cluster of antigen presenting OLs identified by Sadick et al. (2022). Moreover, these cells were not characterized by the expression of neither *C4b* nor *Serpina3*, which constitute the key markers of reactive OLs, alias DOLs.

The lack of immune OL signature in AD samples was recently scrutinized by Pandey et al. (2022). Using multi-dataset integration, the authors defined three distinct activation states of OLs across the mouse models of AD and MS (MOL-DA1, MOL-DA2, and MOL-IFN), which were characterized by expression of inflammatory-, survival- and interferon-associated genes (Table 2). Follow-up integrative analysis of human OL datasets revealed similar gene signatures in MS patients, but not in AD, indicating a distinct transcriptional response of OLs in human AD pathology. The latest contribution to the understanding of OL heterogeneity in neurodegeneration was provided by Kaya et al. (2022), who studied WM aging in mouse. The authors identified clusters of aging-related Serpina3n+ *C4b*+ OLs (AROs) and interferon-responsive *Stat1*+ *B2m*+ OLs (IROs) characterized by the expression of type I interferon response genes and MHC-I genes (Table 2). The two populations resembled the inflammatory- and interferon- clusters described by Pandey et al. (2022), but the population presumably involved in the OL survival (MOL-DA2) was missing. Altogether, the data indicates shared, but also distinct response of OLs in different pathologies that requests further investigation.

To date, single-cell and single-nucleus transcriptomics have been applied to most neurodegenerative and neuropsychiatric disorders, e.g., amyotrophic lateral sclerosis (Pineda et al., 2021), Parkinson’s disease (Smajic et al., 2022), schizophrenia (Ruzicka et al., 2020), major depressive disorders (Nagy et al., 2020),
and autism (Velmeshev et al., 2019). Unfortunately, the analysis of OLs has often not been of primary interest and therefore not explored in detail. Other CNS disorders with a recently discovered role of OLs in its disease etiology, e.g., epilepsy (Knowles et al., 2022), are still awaiting in-depth single-cell transcriptomic characterization. Attention is also required for the OLs in the acute CNS injuries, where their role is largely unexplored.

**Conclusion**

We provide a comprehensive overview of key studies defining the current spectrum of OL heterogeneity in health and disease. We document a first standardized OL nomenclature in murine healthy CNS and strong indication of distinct reactive immune OL gene signature present in multiple models of CNS pathologies. OL heterogeneity in human is less defined and there are distinct transcriptional OL phenotypes present in MS and AD patients. Future studies are needed to establish a robust nomenclature of human OLs and characterize the full spectrum of OL activation states in other CNS disorders.

**Author contributions**

LV, ZM, and DZ drafted the manuscript. RK, SB, PA, MK, and MA participated in subsequent review and editing process. All authors have read and agreed to the published version of the manuscript.

**References**

Bakken, T. E., Jorstad, N. L., Hu, Q., Lake, B. B., Tian, W., Kalmbach, B. E., et al. (2021). Comparative cellular analysis of motor cortex in human, mammoset and mouse. *Nature* 598, 111–119. doi: 10.1038/s41586-021-03465-8

Bartosovic, M., Kabbage, M., and Castelo-Branco, G. (2021). Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues. *Nat. Biotechnol.* 39, 825–835. doi: 10.1038/s41587-021-00869-9

BIGCCN (2021). A multimodal cell census and atlas of the mammalian primary motor cortex. *Nature* 598, 86–102. doi: 10.1038/s41586-021-03950-0

Chen, W. T., Lu, A., Craesæerts, K., Pavie, B., Sala Frigerio, C., Corthout, N., et al. (2020). Spatial transcriptomics and in situ sequencing to study alzheimer’s disease. *Cell* 182:e919. doi: 10.1016/j.cell.2020.06.038

Del Río-Hortega, P. (1921). Estudios sobre la neurogia. La glia de escasas redes. (oligodendroglia). *Bol. Real Soc. Esp. Hist. Nat.* 21, 63–92.

Del-Aguila, J. L., Li, Z., Dubé, U., Mihindukulasuriya, K. A., Budde, J. P., Fernandez, M. V., et al. (2019). A single-nucleus RNA sequencing study of Mendelian and sporadic AD in the human brain. *Alzheimer’s Res. Ther.* 11:71. doi: 10.1186/s13195-019-0524-x

Falcao, A. M., van Bruggen, D., Marques, S., Meijer, M., Jäkel, S., Agirre, E., et al. (2018). Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. *Nat. Med.* 24, 1837–1844. doi: 10.1038/nm.41591-018-0236-y

Floriddia, E. M., Lourenco, T., Zhang, S., van Bruggen, D., Hilscher, M. M., Kukanja, P., et al. (2020). Distinct oligodendrocyte populations have spatial preference and different responses to spinal cord injury. *Nat. Commun.* 11:5860. doi: 10.1038/s41467-020-19453-x

Gerrits, E., Brouwer, N., Kooistra, S. M., Woodbury, M. E., Vermeiren, Y., Lambourne, M., et al. (2021). Distinct amyloid-beta and tau-associated microglia profiles in Alzheimer’s disease. *Acta Neuropathol.* 141, 681–696. doi: 10.1007/s00401-021-02263-w

Grubman, A., Chew, G., Ouyang, J. F., Sun, G., Choo, Y. Y., McLean, C., et al. (2019). A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. *Nat. Neurosci.* 22, 2087–2097. doi: 10.1038/s41593-019-0539-4

Habib, N., Arv罕am-Davidl, I., Basu, A., Burks, T., Shekhzt, K., Hofree, M., et al. (2017). Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat. Methods* 14, 955–958. doi: 10.1038/nmeth.4407

Hilscher, M. M., Langseth, C. M., Kukanja, P., Yokota, C., Nilsson, M., and Castelo-Branco, G. (2022). Spatial and temporal heterogeneity in the lineage progression of fine oligodendrocyte subtypes. *BMC Biol.* 20:122. doi: 10.1186/s12915-022-01325-z

Jäkel, S., Agirre, E., Mendana Falcao, A., van Bruggen, D., Lee, K. W., Knuesel, I., et al. (2019). Altered human oligodendrocyte heterogeneity in multiple sclerosis. *Nature* 566, 543–547. doi: 10.1038/s41586-019-0903-2

**Funding**

This study was supported by project LX22NPO5107 (MEYS): Financed by EU—Next Generation EU and institutional support RVO 86652036.

**Acknowledgments**

We thank Ravindra Naraine for his assistance with language editing.

**Conflict of interest**

Author MK was employed by TATAA Biocenter AB.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Valihrach et al. 10.3389/fncel.2022.1025012

A. B., Skene, N., et al. (2020). Probabilistic cell typing enables fine mapping of bioRxiv

M. E., et al. (2021). Single-cell profiling of the human primary motor cortex in ALS Cell Rep.

Disease-associated oligodendrocyte responses across neurodegenerative disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nat. Neurosci. 23, 771–781. doi: 10.1038/s41593-020-00764-7

Lake, B. B., Chen, S., Soo, B. C., Fan, J., Kaiser, G. E., Yung, Y. C., et al. (2018). Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 36, 70–80. doi: 10.1038/nbt.4038

Lau, S. F., Cao, H., Fu, A. K. Y., and Ip, N. Y. (2020). Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 117, 25800–25809. doi: 10.1073/pnas.2008762117

Lee, S. H., Rezzonico, M. G., Friedman, B. A., Huntley, M. H., Meilandt, W. J., Pandey, S., et al. (2021). TREM2-independent oligodendrocyte, astrocyte, and T cell responses to tau and amyloid pathology in mouse models of Alzheimer disease. Cell Rep. 37:110158. doi: 10.1016/j.celrep.2021.110158

Leng, K., Li, E., Eser, R., Piersig, A., Sit, R., Tan, M., et al. (2021). Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease. Nat. Neurosci. 24, 276–287. doi: 10.1038/s41593-020-00764-7

Marques, S., Zeisel, A., Codeluppi, S., van Bruggen, D., Mandhana Falcao, A., Xiao, L., et al. (2016). Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science 352, 1326–1329. doi: 10.1126/science.aaf6463

Martbys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., et al. (2019). Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570, 332–337. doi: 10.1038/s41586-019-1195-2

Meijer, M., Agire, E., Kabbe, M., van Tuin, C. A., Heskol, A., Zheng, C., et al. (2022). Epigenomic priming of immune genes implicates oligodendroglia in multiple sclerosis susceptibility. Neuron 110:e11113.

Morabito, S., Miyoshi, E., Michael, N., Shahn, S., Martin, A. C., Head, E., et al. (2021). Single-cell chromosome accessibility and transcriptomic characterization of Alzheimer’s disease. Nat. Genet. 53, 1143–1155.

Nagy, C., Maitra, M., Tanti, A., Suderman, M., Theroux, J. F., Davoli, M. A., et al. (2020). Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nat. Neurosci. 23, 771–781. doi: 10.1038/s41593-020-00621-y

Pandey, S., Shen, K., Lee, S. H., Shen, Y. A., Wang, Y., Otero-Garcia, M., et al. (2022). Disease-associated oligodendrocyte responses across neurodegenerative diseases. Cell Rep. 40:111189. doi: 10.1016/j.celrep.2021.111189

Pineda, S. S., Lee, H., Fitzwaltzer, B. E., Mohammadi, S., Pregent, L. J., Gardaolithi, M. E., et al. (2021). Single-cell profiling of the human primary motor cortex in ALS and FTLD. bioRxiv [Preprint]. doi: 10.1101/2021.07.07.451374

Qian, X., Harris, K. D., Hauling, T., Nicoloutsopoulos, D., Munoz-Manchado, A. B., Skene, N., et al. (2020). Probabilistic cell typing enables fine mapping of closely related cell types in situ. Nat. Methods 17, 101–106. doi: 10.1038/s41592-019-0631-4

Russ, D. E., Cross, R. B. P., Li, L., Koch, S. C., Matson, K. J. E., Yadav, A., et al. (2021). A harmonized atlas of mouse spinal cord cell types and their spatial organization. Nat. Commun. 12:5722. doi: 10.1038/s41467-021-25125-1

Ruzicka, W. B., Mohammadi, S., Davila-Velderrain, J., Subburaju, S., Tso, D. R., Hourihan, M., et al. (2020). Single-cell dissection of schizophrenia reveals neurodevelopmental-synaptic axis and transcriptional resilience. medRxiv [Preprint]. doi: 10.1101/2020.11.06.20223542

Sadick, J. S., O’Dea, M. R., Hasel, P., Dykstra, T., Faustin, A., and Dietrich, C., et al. (2022). Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer’s disease. Neuron 110, 1788–1805.e1710. doi: 10.1016/j.neuron.2022.03.008

Sezer, L. A., and Williams, A. (2022). Oligodendrogliosis heterogeneity in the human central nervous system. Acta Neuropathol. 143, 143–157. doi: 10.1007/s00401-021-02390-4

Smajic, S., Prada-Medina, C. A., Landolusi, Z., Ghelli, J., Delcambre, S., Dietrich, C., et al. (2022). Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 145, 964–978. doi: 10.1093/brain/awab446

Stuart, T., and Satija, R. (2019). Integrative single-cell analysis. Nat. Rev. Genet. 20, 257–272. doi: 10.1038/s41576-019-00993-7

Svensson, V., da Veiga Beltrame, E., and Pachter, L. (2020). A curated database reveals trends in single-cell transcriptomics. Database 2020:baa073. doi: 10.1093/database/baa073

Velmeshev, D., Schirmer, L., Jung, D., Haessler, M., Perez, Y., Mayer, S., et al. (2019). Single-cell genomics identifies cell type-specific molecular changes in autism. Science 364, 685–689. doi: 10.1126/science.aaq1830

Yadav, A., Matson, K. J. E., Li, L., Hua, I., Petscuso, J., Kang, K., et al. (2022). A Cellular Taxonomy of the Adult Human Spinal Cord. bioRxiv [Preprint]. doi: 10.1101/2022.03.25.485808

Yao, Z., Liu, H., Xie, F., Fischer, S., Adkins, R. S., Aldridge, A. I., et al. (2021). A transcriptomic and epigenomic cell atlas of the mouse primary motor cortex. Nature 598, 103–110. doi: 10.1038/s41586-021-03500-8

Zeisel, A., Hoischen, L., Londerberg, L., Johnson, A., Memis, F., van der Zwan, J., et al. (2020a). Molecular Architecture of the Mouse Nervous System. Cell 174:e1022. doi: 10.1016/j.cell.2018.06.021

Zeisel, A., Munoz-Manchado, A. B., Codeluppi, S., Londerberg, P., La Mano, G., Jureus, M., et al. (2015). Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-sequencing. Science 347, 1138–1142. doi: 10.1126/science.aaa1934

Zhang, M., Eichhorn, S. W., Zingg, B., Yao, Z., Cotter, K., Zeng, H., et al. (2021). Spatially resolved cell atlas of the mouse primary motor cortex by MERFISH. Nature 598, 137–143. doi: 10.1038/s41586-021-03705-x

Zhou, Y., Song, W. M., Anthey, P. S., Swain, A., Levy, T., and Miller, K. R., et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142. doi: 10.1038/s41591-019-0695-9